nodes	percent_of_prediction	percent_of_DWPC	metapath
Temsirolimus—Protein Kinase Inhibitors—Vemurafenib—melanoma	0.478	1	CiPCiCtD
Temsirolimus—kidney cancer—melanoma	0.303	1	CtDrD
Temsirolimus—ABCB1—melanoma	0.0478	1	CbGaD
Temsirolimus—CYP3A4—Temozolomide—melanoma	0.0141	0.189	CbGbCtD
Temsirolimus—CYP2D6—Vemurafenib—melanoma	0.0122	0.163	CbGbCtD
Temsirolimus—CYP3A7—Docetaxel—melanoma	0.00908	0.122	CbGbCtD
Temsirolimus—CYP3A7-CYP3A51P—Docetaxel—melanoma	0.00908	0.122	CbGbCtD
Temsirolimus—ABCB1—Dactinomycin—melanoma	0.00859	0.115	CbGbCtD
Temsirolimus—CYP3A4—Vemurafenib—melanoma	0.00774	0.104	CbGbCtD
Temsirolimus—CYP3A5—Docetaxel—melanoma	0.00681	0.0912	CbGbCtD
Temsirolimus—ABCB1—Docetaxel—melanoma	0.00443	0.0593	CbGbCtD
Temsirolimus—CYP3A4—Docetaxel—melanoma	0.00266	0.0356	CbGbCtD
Temsirolimus—MTOR—leg—melanoma	0.00193	0.169	CbGeAlD
Temsirolimus—MTOR—hindlimb—melanoma	0.00173	0.151	CbGeAlD
Temsirolimus—MTOR—appendage—melanoma	0.00148	0.13	CbGeAlD
Temsirolimus—MTOR—blood vessel—melanoma	0.000824	0.0721	CbGeAlD
Temsirolimus—Sirolimus—FGF2—melanoma	0.000718	0.701	CrCbGaD
Temsirolimus—MTOR—neck—melanoma	0.00059	0.0516	CbGeAlD
Temsirolimus—FKBP1A—neck—melanoma	0.00053	0.0464	CbGeAlD
Temsirolimus—MTOR—eye—melanoma	0.000439	0.0384	CbGeAlD
Temsirolimus—MTOR—retina—melanoma	0.000435	0.038	CbGeAlD
Temsirolimus—FKBP1A—eye—melanoma	0.000395	0.0345	CbGeAlD
Temsirolimus—FKBP1A—retina—melanoma	0.000391	0.0342	CbGeAlD
Temsirolimus—MTOR—skin of body—melanoma	0.000382	0.0334	CbGeAlD
Temsirolimus—MTOR—mammalian vulva—melanoma	0.000348	0.0305	CbGeAlD
Temsirolimus—FKBP1A—skin of body—melanoma	0.000343	0.03	CbGeAlD
Temsirolimus—FKBP1A—mammalian vulva—melanoma	0.000313	0.0274	CbGeAlD
Temsirolimus—MTOR—head—melanoma	0.000249	0.0218	CbGeAlD
Temsirolimus—FKBP1A—head—melanoma	0.000224	0.0196	CbGeAlD
Temsirolimus—MTOR—lymph node—melanoma	0.000174	0.0153	CbGeAlD
Temsirolimus—ABCB1—blood vessel—melanoma	0.000172	0.015	CbGeAlD
Temsirolimus—FKBP1A—lymph node—melanoma	0.000157	0.0137	CbGeAlD
Temsirolimus—Tacrolimus—ALB—melanoma	0.000105	0.103	CrCbGaD
Temsirolimus—Sirolimus—ABCB1—melanoma	0.000101	0.0982	CrCbGaD
Temsirolimus—Tacrolimus—ABCB1—melanoma	0.000101	0.0982	CrCbGaD
Temsirolimus—Dysuria—Temozolomide—melanoma	9.69e-05	0.00225	CcSEcCtD
Temsirolimus—Neutropenia—Temozolomide—melanoma	9.69e-05	0.00225	CcSEcCtD
Temsirolimus—Hyperglycaemia—Carmustine—melanoma	9.67e-05	0.00225	CcSEcCtD
Temsirolimus—Upper respiratory tract infection—Temozolomide—melanoma	9.63e-05	0.00224	CcSEcCtD
Temsirolimus—Pneumonia—Carmustine—melanoma	9.62e-05	0.00223	CcSEcCtD
Temsirolimus—Pollakiuria—Temozolomide—melanoma	9.57e-05	0.00222	CcSEcCtD
Temsirolimus—Depression—Carmustine—melanoma	9.53e-05	0.00221	CcSEcCtD
Temsirolimus—Sepsis—Docetaxel—melanoma	9.53e-05	0.00221	CcSEcCtD
Temsirolimus—Renal failure—Carmustine—melanoma	9.4e-05	0.00218	CcSEcCtD
Temsirolimus—Weight decreased—Temozolomide—melanoma	9.38e-05	0.00218	CcSEcCtD
Temsirolimus—Hyperglycaemia—Temozolomide—melanoma	9.35e-05	0.00217	CcSEcCtD
Temsirolimus—Stomatitis—Carmustine—melanoma	9.32e-05	0.00216	CcSEcCtD
Temsirolimus—Urinary tract infection—Carmustine—melanoma	9.29e-05	0.00216	CcSEcCtD
Temsirolimus—Pneumonia—Temozolomide—melanoma	9.29e-05	0.00216	CcSEcCtD
Temsirolimus—Infestation NOS—Temozolomide—melanoma	9.24e-05	0.00215	CcSEcCtD
Temsirolimus—Infestation—Temozolomide—melanoma	9.24e-05	0.00215	CcSEcCtD
Temsirolimus—Depression—Temozolomide—melanoma	9.21e-05	0.00214	CcSEcCtD
Temsirolimus—Thrombophlebitis—Docetaxel—melanoma	9.21e-05	0.00214	CcSEcCtD
Temsirolimus—Blood alkaline phosphatase increased—Docetaxel—melanoma	9.17e-05	0.00213	CcSEcCtD
Temsirolimus—Stevens-Johnson syndrome—Temozolomide—melanoma	9.16e-05	0.00213	CcSEcCtD
Temsirolimus—Body temperature increased—Vemurafenib—melanoma	9.12e-05	0.00212	CcSEcCtD
Temsirolimus—Pharyngitis—Dactinomycin—melanoma	9.1e-05	0.00211	CcSEcCtD
Temsirolimus—ABCB1—retina—melanoma	9.05e-05	0.00791	CbGeAlD
Temsirolimus—Swelling—Docetaxel—melanoma	9.04e-05	0.0021	CcSEcCtD
Temsirolimus—Stomatitis—Temozolomide—melanoma	9.01e-05	0.00209	CcSEcCtD
Temsirolimus—Urinary tract infection—Temozolomide—melanoma	8.98e-05	0.00209	CcSEcCtD
Temsirolimus—Chills—Bleomycin—melanoma	8.82e-05	0.00205	CcSEcCtD
Temsirolimus—Erythema multiforme—Dactinomycin—melanoma	8.67e-05	0.00201	CcSEcCtD
Temsirolimus—Sinusitis—Temozolomide—melanoma	8.67e-05	0.00201	CcSEcCtD
Temsirolimus—Erythema—Bleomycin—melanoma	8.56e-05	0.00199	CcSEcCtD
Temsirolimus—Hypersensitivity—Vemurafenib—melanoma	8.5e-05	0.00197	CcSEcCtD
Temsirolimus—Oedema peripheral—Carmustine—melanoma	8.46e-05	0.00196	CcSEcCtD
Temsirolimus—Connective tissue disorder—Carmustine—melanoma	8.44e-05	0.00196	CcSEcCtD
Temsirolimus—Dermatitis bullous—Docetaxel—melanoma	8.34e-05	0.00194	CcSEcCtD
Temsirolimus—Asthenia—Vemurafenib—melanoma	8.27e-05	0.00192	CcSEcCtD
Temsirolimus—Pharyngitis—Temozolomide—melanoma	8.23e-05	0.00191	CcSEcCtD
Temsirolimus—Chills—Dactinomycin—melanoma	8.23e-05	0.00191	CcSEcCtD
Temsirolimus—Urinary tract disorder—Temozolomide—melanoma	8.19e-05	0.0019	CcSEcCtD
Temsirolimus—Oedema peripheral—Temozolomide—melanoma	8.17e-05	0.0019	CcSEcCtD
Temsirolimus—Pruritus—Vemurafenib—melanoma	8.16e-05	0.00189	CcSEcCtD
Temsirolimus—Connective tissue disorder—Temozolomide—melanoma	8.15e-05	0.00189	CcSEcCtD
Temsirolimus—Urethral disorder—Temozolomide—melanoma	8.13e-05	0.00189	CcSEcCtD
Temsirolimus—Eye disorder—Carmustine—melanoma	8.02e-05	0.00186	CcSEcCtD
Temsirolimus—Erythema—Dactinomycin—melanoma	7.98e-05	0.00185	CcSEcCtD
Temsirolimus—Gastrointestinal haemorrhage—Docetaxel—melanoma	7.97e-05	0.00185	CcSEcCtD
Temsirolimus—Anaemia—Bleomycin—melanoma	7.91e-05	0.00184	CcSEcCtD
Temsirolimus—Diarrhoea—Vemurafenib—melanoma	7.89e-05	0.00183	CcSEcCtD
Temsirolimus—Erythema multiforme—Temozolomide—melanoma	7.84e-05	0.00182	CcSEcCtD
Temsirolimus—Eye disorder—Temozolomide—melanoma	7.75e-05	0.0018	CcSEcCtD
Temsirolimus—Cardiac disorder—Temozolomide—melanoma	7.7e-05	0.00179	CcSEcCtD
Temsirolimus—Leukopenia—Bleomycin—melanoma	7.66e-05	0.00178	CcSEcCtD
Temsirolimus—Dizziness—Vemurafenib—melanoma	7.63e-05	0.00177	CcSEcCtD
Temsirolimus—Angiopathy—Temozolomide—melanoma	7.53e-05	0.00175	CcSEcCtD
Temsirolimus—Mental disorder—Carmustine—melanoma	7.52e-05	0.00175	CcSEcCtD
Temsirolimus—Immune system disorder—Temozolomide—melanoma	7.49e-05	0.00174	CcSEcCtD
Temsirolimus—Mediastinal disorder—Temozolomide—melanoma	7.48e-05	0.00174	CcSEcCtD
Temsirolimus—Erythema—Carmustine—melanoma	7.47e-05	0.00174	CcSEcCtD
Temsirolimus—Malnutrition—Carmustine—melanoma	7.47e-05	0.00174	CcSEcCtD
Temsirolimus—Cough—Bleomycin—melanoma	7.47e-05	0.00173	CcSEcCtD
Temsirolimus—Chills—Temozolomide—melanoma	7.44e-05	0.00173	CcSEcCtD
Temsirolimus—Dehydration—Docetaxel—melanoma	7.42e-05	0.00172	CcSEcCtD
Temsirolimus—Anaemia—Dactinomycin—melanoma	7.38e-05	0.00171	CcSEcCtD
Temsirolimus—Vomiting—Vemurafenib—melanoma	7.33e-05	0.0017	CcSEcCtD
Temsirolimus—Dry skin—Docetaxel—melanoma	7.31e-05	0.0017	CcSEcCtD
Temsirolimus—Myalgia—Bleomycin—melanoma	7.29e-05	0.00169	CcSEcCtD
Temsirolimus—Chest pain—Bleomycin—melanoma	7.29e-05	0.00169	CcSEcCtD
Temsirolimus—Rash—Vemurafenib—melanoma	7.27e-05	0.00169	CcSEcCtD
Temsirolimus—Mental disorder—Temozolomide—melanoma	7.27e-05	0.00169	CcSEcCtD
Temsirolimus—Dermatitis—Vemurafenib—melanoma	7.26e-05	0.00169	CcSEcCtD
Temsirolimus—ABCB1—mammalian vulva—melanoma	7.24e-05	0.00634	CbGeAlD
Temsirolimus—Back pain—Carmustine—melanoma	7.23e-05	0.00168	CcSEcCtD
Temsirolimus—Headache—Vemurafenib—melanoma	7.22e-05	0.00168	CcSEcCtD
Temsirolimus—Erythema—Temozolomide—melanoma	7.22e-05	0.00168	CcSEcCtD
Temsirolimus—Malnutrition—Temozolomide—melanoma	7.22e-05	0.00168	CcSEcCtD
Temsirolimus—CYP2D6—head—melanoma	7.2e-05	0.0063	CbGeAlD
Temsirolimus—Aspartate aminotransferase increased—Docetaxel—melanoma	7.18e-05	0.00167	CcSEcCtD
Temsirolimus—Leukopenia—Dactinomycin—melanoma	7.15e-05	0.00166	CcSEcCtD
Temsirolimus—Dysgeusia—Temozolomide—melanoma	7.07e-05	0.00164	CcSEcCtD
Temsirolimus—Alanine aminotransferase increased—Docetaxel—melanoma	7.03e-05	0.00163	CcSEcCtD
Temsirolimus—Oedema—Bleomycin—melanoma	6.99e-05	0.00162	CcSEcCtD
Temsirolimus—Anaphylactic shock—Bleomycin—melanoma	6.99e-05	0.00162	CcSEcCtD
Temsirolimus—Back pain—Temozolomide—melanoma	6.99e-05	0.00162	CcSEcCtD
Temsirolimus—Infection—Bleomycin—melanoma	6.94e-05	0.00161	CcSEcCtD
Temsirolimus—Anaemia—Carmustine—melanoma	6.91e-05	0.0016	CcSEcCtD
Temsirolimus—Dysphagia—Docetaxel—melanoma	6.89e-05	0.0016	CcSEcCtD
Temsirolimus—Nausea—Vemurafenib—melanoma	6.85e-05	0.00159	CcSEcCtD
Temsirolimus—Thrombocytopenia—Bleomycin—melanoma	6.84e-05	0.00159	CcSEcCtD
Temsirolimus—Myalgia—Dactinomycin—melanoma	6.8e-05	0.00158	CcSEcCtD
Temsirolimus—Leukopenia—Carmustine—melanoma	6.69e-05	0.00155	CcSEcCtD
Temsirolimus—Anaemia—Temozolomide—melanoma	6.67e-05	0.00155	CcSEcCtD
Temsirolimus—Anorexia—Bleomycin—melanoma	6.66e-05	0.00155	CcSEcCtD
Temsirolimus—Angioedema—Temozolomide—melanoma	6.6e-05	0.00153	CcSEcCtD
Temsirolimus—Oedema—Dactinomycin—melanoma	6.52e-05	0.00151	CcSEcCtD
Temsirolimus—Convulsion—Carmustine—melanoma	6.47e-05	0.0015	CcSEcCtD
Temsirolimus—Infection—Dactinomycin—melanoma	6.47e-05	0.0015	CcSEcCtD
Temsirolimus—Leukopenia—Temozolomide—melanoma	6.46e-05	0.0015	CcSEcCtD
Temsirolimus—Hypertension—Carmustine—melanoma	6.45e-05	0.0015	CcSEcCtD
Temsirolimus—Neutropenia—Docetaxel—melanoma	6.44e-05	0.0015	CcSEcCtD
Temsirolimus—Thrombocytopenia—Dactinomycin—melanoma	6.38e-05	0.00148	CcSEcCtD
Temsirolimus—Musculoskeletal discomfort—Bleomycin—melanoma	6.37e-05	0.00148	CcSEcCtD
Temsirolimus—Chest pain—Carmustine—melanoma	6.36e-05	0.00148	CcSEcCtD
Temsirolimus—Myalgia—Carmustine—melanoma	6.36e-05	0.00148	CcSEcCtD
Temsirolimus—Anxiety—Carmustine—melanoma	6.34e-05	0.00147	CcSEcCtD
Temsirolimus—Cough—Temozolomide—melanoma	6.3e-05	0.00146	CcSEcCtD
Temsirolimus—Convulsion—Temozolomide—melanoma	6.26e-05	0.00145	CcSEcCtD
Temsirolimus—Weight decreased—Docetaxel—melanoma	6.24e-05	0.00145	CcSEcCtD
Temsirolimus—Hypertension—Temozolomide—melanoma	6.23e-05	0.00145	CcSEcCtD
Temsirolimus—Dyspnoea—Bleomycin—melanoma	6.23e-05	0.00145	CcSEcCtD
Temsirolimus—Anorexia—Dactinomycin—melanoma	6.21e-05	0.00144	CcSEcCtD
Temsirolimus—Pneumonia—Docetaxel—melanoma	6.18e-05	0.00144	CcSEcCtD
Temsirolimus—Arthralgia—Temozolomide—melanoma	6.15e-05	0.00143	CcSEcCtD
Temsirolimus—Myalgia—Temozolomide—melanoma	6.15e-05	0.00143	CcSEcCtD
Temsirolimus—Infestation—Docetaxel—melanoma	6.15e-05	0.00143	CcSEcCtD
Temsirolimus—Infestation NOS—Docetaxel—melanoma	6.15e-05	0.00143	CcSEcCtD
Temsirolimus—Anxiety—Temozolomide—melanoma	6.13e-05	0.00142	CcSEcCtD
Temsirolimus—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	6.11e-05	0.00142	CcSEcCtD
Temsirolimus—Oedema—Carmustine—melanoma	6.1e-05	0.00142	CcSEcCtD
Temsirolimus—Stevens-Johnson syndrome—Docetaxel—melanoma	6.09e-05	0.00141	CcSEcCtD
Temsirolimus—Decreased appetite—Bleomycin—melanoma	6.07e-05	0.00141	CcSEcCtD
Temsirolimus—Infection—Carmustine—melanoma	6.06e-05	0.00141	CcSEcCtD
Temsirolimus—Renal failure—Docetaxel—melanoma	6.04e-05	0.0014	CcSEcCtD
Temsirolimus—Stomatitis—Docetaxel—melanoma	5.99e-05	0.00139	CcSEcCtD
Temsirolimus—Pain—Bleomycin—melanoma	5.97e-05	0.00139	CcSEcCtD
Temsirolimus—Conjunctivitis—Docetaxel—melanoma	5.97e-05	0.00139	CcSEcCtD
Temsirolimus—Thrombocytopenia—Carmustine—melanoma	5.97e-05	0.00139	CcSEcCtD
Temsirolimus—Musculoskeletal discomfort—Dactinomycin—melanoma	5.94e-05	0.00138	CcSEcCtD
Temsirolimus—Anaphylactic shock—Temozolomide—melanoma	5.89e-05	0.00137	CcSEcCtD
Temsirolimus—Oedema—Temozolomide—melanoma	5.89e-05	0.00137	CcSEcCtD
Temsirolimus—Infection—Temozolomide—melanoma	5.86e-05	0.00136	CcSEcCtD
Temsirolimus—Anorexia—Carmustine—melanoma	5.81e-05	0.00135	CcSEcCtD
Temsirolimus—Epistaxis—Docetaxel—melanoma	5.8e-05	0.00135	CcSEcCtD
Temsirolimus—Nervous system disorder—Temozolomide—melanoma	5.78e-05	0.00134	CcSEcCtD
Temsirolimus—Thrombocytopenia—Temozolomide—melanoma	5.77e-05	0.00134	CcSEcCtD
Temsirolimus—Skin disorder—Temozolomide—melanoma	5.72e-05	0.00133	CcSEcCtD
Temsirolimus—Decreased appetite—Dactinomycin—melanoma	5.66e-05	0.00132	CcSEcCtD
Temsirolimus—Fatigue—Dactinomycin—melanoma	5.62e-05	0.0013	CcSEcCtD
Temsirolimus—Anorexia—Temozolomide—melanoma	5.62e-05	0.0013	CcSEcCtD
Temsirolimus—Pain—Dactinomycin—melanoma	5.57e-05	0.00129	CcSEcCtD
Temsirolimus—Musculoskeletal discomfort—Carmustine—melanoma	5.56e-05	0.00129	CcSEcCtD
Temsirolimus—Rhinitis—Docetaxel—melanoma	5.53e-05	0.00128	CcSEcCtD
Temsirolimus—Body temperature increased—Bleomycin—melanoma	5.52e-05	0.00128	CcSEcCtD
Temsirolimus—Insomnia—Carmustine—melanoma	5.52e-05	0.00128	CcSEcCtD
Temsirolimus—Pharyngitis—Docetaxel—melanoma	5.48e-05	0.00127	CcSEcCtD
Temsirolimus—Urinary tract disorder—Docetaxel—melanoma	5.45e-05	0.00127	CcSEcCtD
Temsirolimus—Dyspnoea—Carmustine—melanoma	5.44e-05	0.00126	CcSEcCtD
Temsirolimus—Oedema peripheral—Docetaxel—melanoma	5.43e-05	0.00126	CcSEcCtD
Temsirolimus—Somnolence—Carmustine—melanoma	5.42e-05	0.00126	CcSEcCtD
Temsirolimus—Connective tissue disorder—Docetaxel—melanoma	5.42e-05	0.00126	CcSEcCtD
Temsirolimus—Urethral disorder—Docetaxel—melanoma	5.41e-05	0.00126	CcSEcCtD
Temsirolimus—Musculoskeletal discomfort—Temozolomide—melanoma	5.37e-05	0.00125	CcSEcCtD
Temsirolimus—Insomnia—Temozolomide—melanoma	5.33e-05	0.00124	CcSEcCtD
Temsirolimus—Gastrointestinal pain—Dactinomycin—melanoma	5.33e-05	0.00124	CcSEcCtD
Temsirolimus—Decreased appetite—Carmustine—melanoma	5.3e-05	0.00123	CcSEcCtD
Temsirolimus—Gastrointestinal disorder—Carmustine—melanoma	5.27e-05	0.00122	CcSEcCtD
Temsirolimus—Dyspnoea—Temozolomide—melanoma	5.25e-05	0.00122	CcSEcCtD
Temsirolimus—Somnolence—Temozolomide—melanoma	5.24e-05	0.00122	CcSEcCtD
Temsirolimus—Erythema multiforme—Docetaxel—melanoma	5.22e-05	0.00121	CcSEcCtD
Temsirolimus—Pain—Carmustine—melanoma	5.22e-05	0.00121	CcSEcCtD
Temsirolimus—Constipation—Carmustine—melanoma	5.22e-05	0.00121	CcSEcCtD
Temsirolimus—ABCB1—head—melanoma	5.18e-05	0.00453	CbGeAlD
Temsirolimus—Eye disorder—Docetaxel—melanoma	5.16e-05	0.0012	CcSEcCtD
Temsirolimus—Abdominal pain—Dactinomycin—melanoma	5.15e-05	0.0012	CcSEcCtD
Temsirolimus—Body temperature increased—Dactinomycin—melanoma	5.15e-05	0.0012	CcSEcCtD
Temsirolimus—Hypersensitivity—Bleomycin—melanoma	5.15e-05	0.0012	CcSEcCtD
Temsirolimus—Decreased appetite—Temozolomide—melanoma	5.12e-05	0.00119	CcSEcCtD
Temsirolimus—Cardiac disorder—Docetaxel—melanoma	5.12e-05	0.00119	CcSEcCtD
Temsirolimus—Gastrointestinal disorder—Temozolomide—melanoma	5.09e-05	0.00118	CcSEcCtD
Temsirolimus—Fatigue—Temozolomide—melanoma	5.08e-05	0.00118	CcSEcCtD
Temsirolimus—Pain—Temozolomide—melanoma	5.04e-05	0.00117	CcSEcCtD
Temsirolimus—Constipation—Temozolomide—melanoma	5.04e-05	0.00117	CcSEcCtD
Temsirolimus—Asthenia—Bleomycin—melanoma	5.01e-05	0.00116	CcSEcCtD
Temsirolimus—Angiopathy—Docetaxel—melanoma	5.01e-05	0.00116	CcSEcCtD
Temsirolimus—Gastrointestinal pain—Carmustine—melanoma	4.99e-05	0.00116	CcSEcCtD
Temsirolimus—Immune system disorder—Docetaxel—melanoma	4.98e-05	0.00116	CcSEcCtD
Temsirolimus—Mediastinal disorder—Docetaxel—melanoma	4.97e-05	0.00115	CcSEcCtD
Temsirolimus—Chills—Docetaxel—melanoma	4.95e-05	0.00115	CcSEcCtD
Temsirolimus—Pruritus—Bleomycin—melanoma	4.94e-05	0.00115	CcSEcCtD
Temsirolimus—Mental disorder—Docetaxel—melanoma	4.83e-05	0.00112	CcSEcCtD
Temsirolimus—Abdominal pain—Carmustine—melanoma	4.82e-05	0.00112	CcSEcCtD
Temsirolimus—Body temperature increased—Carmustine—melanoma	4.82e-05	0.00112	CcSEcCtD
Temsirolimus—Gastrointestinal pain—Temozolomide—melanoma	4.82e-05	0.00112	CcSEcCtD
Temsirolimus—Erythema—Docetaxel—melanoma	4.8e-05	0.00112	CcSEcCtD
Temsirolimus—Malnutrition—Docetaxel—melanoma	4.8e-05	0.00112	CcSEcCtD
Temsirolimus—Hypersensitivity—Dactinomycin—melanoma	4.8e-05	0.00111	CcSEcCtD
Temsirolimus—Dysgeusia—Docetaxel—melanoma	4.7e-05	0.00109	CcSEcCtD
Temsirolimus—Asthenia—Dactinomycin—melanoma	4.68e-05	0.00109	CcSEcCtD
Temsirolimus—Abdominal pain—Temozolomide—melanoma	4.66e-05	0.00108	CcSEcCtD
Temsirolimus—Body temperature increased—Temozolomide—melanoma	4.66e-05	0.00108	CcSEcCtD
Temsirolimus—Back pain—Docetaxel—melanoma	4.65e-05	0.00108	CcSEcCtD
Temsirolimus—Hypersensitivity—Carmustine—melanoma	4.49e-05	0.00104	CcSEcCtD
Temsirolimus—Diarrhoea—Dactinomycin—melanoma	4.46e-05	0.00104	CcSEcCtD
Temsirolimus—Vomiting—Bleomycin—melanoma	4.44e-05	0.00103	CcSEcCtD
Temsirolimus—Anaemia—Docetaxel—melanoma	4.44e-05	0.00103	CcSEcCtD
Temsirolimus—Rash—Bleomycin—melanoma	4.41e-05	0.00102	CcSEcCtD
Temsirolimus—Dermatitis—Bleomycin—melanoma	4.4e-05	0.00102	CcSEcCtD
Temsirolimus—Asthenia—Carmustine—melanoma	4.38e-05	0.00102	CcSEcCtD
Temsirolimus—Hypersensitivity—Temozolomide—melanoma	4.34e-05	0.00101	CcSEcCtD
Temsirolimus—Leukopenia—Docetaxel—melanoma	4.3e-05	0.000998	CcSEcCtD
Temsirolimus—Asthenia—Temozolomide—melanoma	4.23e-05	0.000982	CcSEcCtD
Temsirolimus—Cough—Docetaxel—melanoma	4.19e-05	0.000973	CcSEcCtD
Temsirolimus—Diarrhoea—Carmustine—melanoma	4.17e-05	0.000969	CcSEcCtD
Temsirolimus—Pruritus—Temozolomide—melanoma	4.17e-05	0.000968	CcSEcCtD
Temsirolimus—Convulsion—Docetaxel—melanoma	4.16e-05	0.000966	CcSEcCtD
Temsirolimus—Nausea—Bleomycin—melanoma	4.15e-05	0.000964	CcSEcCtD
Temsirolimus—Hypertension—Docetaxel—melanoma	4.15e-05	0.000963	CcSEcCtD
Temsirolimus—Vomiting—Dactinomycin—melanoma	4.14e-05	0.000962	CcSEcCtD
Temsirolimus—Rash—Dactinomycin—melanoma	4.11e-05	0.000954	CcSEcCtD
Temsirolimus—Arthralgia—Docetaxel—melanoma	4.09e-05	0.00095	CcSEcCtD
Temsirolimus—Chest pain—Docetaxel—melanoma	4.09e-05	0.00095	CcSEcCtD
Temsirolimus—Myalgia—Docetaxel—melanoma	4.09e-05	0.00095	CcSEcCtD
Temsirolimus—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	4.06e-05	0.000943	CcSEcCtD
Temsirolimus—Dizziness—Carmustine—melanoma	4.03e-05	0.000937	CcSEcCtD
Temsirolimus—Diarrhoea—Temozolomide—melanoma	4.03e-05	0.000936	CcSEcCtD
Temsirolimus—Anaphylactic shock—Docetaxel—melanoma	3.92e-05	0.00091	CcSEcCtD
Temsirolimus—Oedema—Docetaxel—melanoma	3.92e-05	0.00091	CcSEcCtD
Temsirolimus—Dizziness—Temozolomide—melanoma	3.9e-05	0.000905	CcSEcCtD
Temsirolimus—Infection—Docetaxel—melanoma	3.89e-05	0.000904	CcSEcCtD
Temsirolimus—Vomiting—Carmustine—melanoma	3.88e-05	0.000901	CcSEcCtD
Temsirolimus—Nausea—Dactinomycin—melanoma	3.87e-05	0.000899	CcSEcCtD
Temsirolimus—Rash—Carmustine—melanoma	3.85e-05	0.000893	CcSEcCtD
Temsirolimus—Nervous system disorder—Docetaxel—melanoma	3.84e-05	0.000893	CcSEcCtD
Temsirolimus—Dermatitis—Carmustine—melanoma	3.84e-05	0.000892	CcSEcCtD
Temsirolimus—Thrombocytopenia—Docetaxel—melanoma	3.84e-05	0.000891	CcSEcCtD
Temsirolimus—Headache—Carmustine—melanoma	3.82e-05	0.000887	CcSEcCtD
Temsirolimus—Skin disorder—Docetaxel—melanoma	3.81e-05	0.000884	CcSEcCtD
Temsirolimus—Vomiting—Temozolomide—melanoma	3.75e-05	0.00087	CcSEcCtD
Temsirolimus—Anorexia—Docetaxel—melanoma	3.74e-05	0.000868	CcSEcCtD
Temsirolimus—Rash—Temozolomide—melanoma	3.72e-05	0.000863	CcSEcCtD
Temsirolimus—Dermatitis—Temozolomide—melanoma	3.71e-05	0.000862	CcSEcCtD
Temsirolimus—Headache—Temozolomide—melanoma	3.69e-05	0.000857	CcSEcCtD
Temsirolimus—ABCB1—lymph node—melanoma	3.63e-05	0.00317	CbGeAlD
Temsirolimus—Nausea—Carmustine—melanoma	3.62e-05	0.000841	CcSEcCtD
Temsirolimus—Musculoskeletal discomfort—Docetaxel—melanoma	3.57e-05	0.000829	CcSEcCtD
Temsirolimus—Insomnia—Docetaxel—melanoma	3.54e-05	0.000823	CcSEcCtD
Temsirolimus—Nausea—Temozolomide—melanoma	3.5e-05	0.000813	CcSEcCtD
Temsirolimus—Dyspnoea—Docetaxel—melanoma	3.49e-05	0.000811	CcSEcCtD
Temsirolimus—Somnolence—Docetaxel—melanoma	3.48e-05	0.000809	CcSEcCtD
Temsirolimus—Decreased appetite—Docetaxel—melanoma	3.41e-05	0.000791	CcSEcCtD
Temsirolimus—Gastrointestinal disorder—Docetaxel—melanoma	3.38e-05	0.000786	CcSEcCtD
Temsirolimus—Fatigue—Docetaxel—melanoma	3.38e-05	0.000785	CcSEcCtD
Temsirolimus—Constipation—Docetaxel—melanoma	3.35e-05	0.000778	CcSEcCtD
Temsirolimus—Pain—Docetaxel—melanoma	3.35e-05	0.000778	CcSEcCtD
Temsirolimus—Gastrointestinal pain—Docetaxel—melanoma	3.2e-05	0.000744	CcSEcCtD
Temsirolimus—Abdominal pain—Docetaxel—melanoma	3.1e-05	0.00072	CcSEcCtD
Temsirolimus—Body temperature increased—Docetaxel—melanoma	3.1e-05	0.00072	CcSEcCtD
Temsirolimus—Hypersensitivity—Docetaxel—melanoma	2.89e-05	0.000671	CcSEcCtD
Temsirolimus—Asthenia—Docetaxel—melanoma	2.81e-05	0.000653	CcSEcCtD
Temsirolimus—Pruritus—Docetaxel—melanoma	2.77e-05	0.000644	CcSEcCtD
Temsirolimus—Diarrhoea—Docetaxel—melanoma	2.68e-05	0.000623	CcSEcCtD
Temsirolimus—Dizziness—Docetaxel—melanoma	2.59e-05	0.000602	CcSEcCtD
Temsirolimus—Vomiting—Docetaxel—melanoma	2.49e-05	0.000579	CcSEcCtD
Temsirolimus—Rash—Docetaxel—melanoma	2.47e-05	0.000574	CcSEcCtD
Temsirolimus—Dermatitis—Docetaxel—melanoma	2.47e-05	0.000573	CcSEcCtD
Temsirolimus—Headache—Docetaxel—melanoma	2.46e-05	0.00057	CcSEcCtD
Temsirolimus—Nausea—Docetaxel—melanoma	2.33e-05	0.000541	CcSEcCtD
Temsirolimus—MTOR—Adaptive Immune System—EGFR—melanoma	2.76e-06	6.66e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—MAP2K1—melanoma	2.76e-06	6.65e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—MAPK1—melanoma	2.75e-06	6.64e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—EGFR—melanoma	2.75e-06	6.64e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—CYP17A1—melanoma	2.75e-06	6.63e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—PIK3CB—melanoma	2.74e-06	6.62e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—EDN1—melanoma	2.74e-06	6.62e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—PIK3CD—melanoma	2.74e-06	6.6e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—PLA2G6—melanoma	2.74e-06	6.6e-05	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—KRAS—melanoma	2.72e-06	6.56e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—BRAF—melanoma	2.7e-06	6.52e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—PLCB4—melanoma	2.7e-06	6.52e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—CSF2—melanoma	2.68e-06	6.47e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—FGF1—melanoma	2.68e-06	6.47e-05	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—ABCB1—melanoma	2.64e-06	6.36e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—CXCL8—melanoma	2.64e-06	6.36e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—E2F1—melanoma	2.63e-06	6.33e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—FGF2—melanoma	2.62e-06	6.32e-05	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—KRAS—melanoma	2.61e-06	6.3e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—melanoma	2.6e-06	6.28e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—KRAS—melanoma	2.6e-06	6.27e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—PDGFRA—melanoma	2.6e-06	6.26e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—GNA11—melanoma	2.6e-06	6.26e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—PLA2G6—melanoma	2.58e-06	6.22e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—CDKN1B—melanoma	2.58e-06	6.21e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—PRKCA—melanoma	2.57e-06	6.2e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—ITGB3—melanoma	2.57e-06	6.2e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—MAP2K1—melanoma	2.55e-06	6.14e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—SLC6A11—melanoma	2.54e-06	6.13e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—PIP4K2A—melanoma	2.54e-06	6.13e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—FASN—melanoma	2.54e-06	6.13e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—PIK3CD—melanoma	2.53e-06	6.1e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—CASP3—melanoma	2.52e-06	6.08e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—SPP1—melanoma	2.52e-06	6.08e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—IL2—melanoma	2.52e-06	6.08e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—melanoma	2.52e-06	6.07e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—MAP2K2—melanoma	2.51e-06	6.06e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—SLC5A5—melanoma	2.5e-06	6.03e-05	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—PIK3CA—melanoma	2.5e-06	6.02e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—BCL2—melanoma	2.49e-06	6e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—MTAP—melanoma	2.47e-06	5.96e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—IFNG—melanoma	2.47e-06	5.95e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—VCAN—melanoma	2.46e-06	5.93e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—CCND1—melanoma	2.46e-06	5.92e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—MDM2—melanoma	2.45e-06	5.91e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—CTNNB1—melanoma	2.43e-06	5.87e-05	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—PRKCA—melanoma	2.43e-06	5.85e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—FGF2—melanoma	2.42e-06	5.84e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—ERBB2—melanoma	2.42e-06	5.83e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—CD44—melanoma	2.41e-06	5.82e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—GNAQ—melanoma	2.41e-06	5.82e-05	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—ERCC2—melanoma	2.41e-06	5.8e-05	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—PIK3CA—melanoma	2.4e-06	5.78e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—TERT—melanoma	2.39e-06	5.76e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—PIK3CA—melanoma	2.39e-06	5.76e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—PIK3CB—melanoma	2.39e-06	5.75e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—MMP9—melanoma	2.39e-06	5.75e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—RAC1—melanoma	2.38e-06	5.75e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—CD4—melanoma	2.38e-06	5.74e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—CDKN1A—melanoma	2.38e-06	5.73e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—PTEN—melanoma	2.37e-06	5.72e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—NFKB1—melanoma	2.36e-06	5.69e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—VCAN—melanoma	2.32e-06	5.59e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—CYP1B1—melanoma	2.32e-06	5.58e-05	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—HRAS—melanoma	2.31e-06	5.57e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—HIF1A—melanoma	2.29e-06	5.51e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—MDM2—melanoma	2.27e-06	5.46e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—CDKN1B—melanoma	2.24e-06	5.4e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—ERBB2—melanoma	2.23e-06	5.38e-05	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—HRAS—melanoma	2.22e-06	5.35e-05	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—IL6—melanoma	2.21e-06	5.33e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—HRAS—melanoma	2.21e-06	5.33e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—PIK3CB—melanoma	2.2e-06	5.31e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—PHGDH—melanoma	2.2e-06	5.31e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—LUM—melanoma	2.2e-06	5.31e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—CD4—melanoma	2.2e-06	5.3e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—IL2—melanoma	2.19e-06	5.29e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—KDR—melanoma	2.19e-06	5.27e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—PTGS2—melanoma	2.18e-06	5.26e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—HPSE—melanoma	2.16e-06	5.21e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—VEGFA—melanoma	2.14e-06	5.16e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—melanoma	2.13e-06	5.13e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—CUBN—melanoma	2.12e-06	5.11e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—STAT3—melanoma	2.12e-06	5.11e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—CTNNB1—melanoma	2.12e-06	5.1e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—NRAS—melanoma	2.12e-06	5.1e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—IL6—melanoma	2.12e-06	5.1e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—FN1—melanoma	2.1e-06	5.07e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—CYP17A1—melanoma	2.08e-06	5e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—CDKN1B—melanoma	2.07e-06	4.99e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—CDKN1A—melanoma	2.07e-06	4.98e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—PTEN—melanoma	2.06e-06	4.97e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—NOTCH1—melanoma	2.06e-06	4.97e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—NFKB1—melanoma	2.05e-06	4.95e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—CSPG4—melanoma	2.05e-06	4.94e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—BSG—melanoma	2.05e-06	4.94e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—SDHD—melanoma	2.05e-06	4.94e-05	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—AKT1—melanoma	2.04e-06	4.92e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—MAPK3—melanoma	2.03e-06	4.88e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—CD80—melanoma	2.02e-06	4.86e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—PIK3CG—melanoma	2.01e-06	4.86e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—APC—melanoma	2.01e-06	4.86e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—KIT—melanoma	2.01e-06	4.86e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—EGF—melanoma	1.99e-06	4.8e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—GPAM—melanoma	1.98e-06	4.78e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—MYC—melanoma	1.97e-06	4.75e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—GNA11—melanoma	1.96e-06	4.73e-05	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—AKT1—melanoma	1.96e-06	4.73e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—CYP17A1—melanoma	1.96e-06	4.72e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—CTNNB1—melanoma	1.95e-06	4.71e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—AKT1—melanoma	1.95e-06	4.7e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—MAPK1—melanoma	1.93e-06	4.65e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—EGFR—melanoma	1.93e-06	4.65e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Transmembrane transport of small molecules—ALB—melanoma	1.92e-06	4.63e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—FASN—melanoma	1.92e-06	4.62e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—CDKN1A—melanoma	1.91e-06	4.6e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—ABCB1—melanoma	1.91e-06	4.6e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—PTEN—melanoma	1.9e-06	4.59e-05	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—PIK3CG—melanoma	1.9e-06	4.58e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—BRAF—melanoma	1.89e-06	4.56e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—SLC5A5—melanoma	1.89e-06	4.55e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—GNA11—melanoma	1.85e-06	4.45e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—STAT3—melanoma	1.84e-06	4.45e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—IGF1—melanoma	1.84e-06	4.45e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—NRAS—melanoma	1.84e-06	4.44e-05	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—PPARG—melanoma	1.84e-06	4.42e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—GNAQ—melanoma	1.82e-06	4.39e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—CD44—melanoma	1.82e-06	4.39e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—KRAS—melanoma	1.82e-06	4.39e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—FASN—melanoma	1.81e-06	4.36e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—MAP2K1—melanoma	1.78e-06	4.3e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—SLC5A5—melanoma	1.78e-06	4.29e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—PIK3CD—melanoma	1.77e-06	4.27e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—MAPK3—melanoma	1.76e-06	4.25e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—PRKCA—melanoma	1.75e-06	4.23e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—CYP1B1—melanoma	1.75e-06	4.21e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—ERCC2—melanoma	1.74e-06	4.2e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—GNAQ—melanoma	1.72e-06	4.14e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—CD44—melanoma	1.72e-06	4.14e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—STAT3—melanoma	1.7e-06	4.11e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—NRAS—melanoma	1.7e-06	4.1e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—FGF2—melanoma	1.7e-06	4.09e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—PLA2G6—melanoma	1.69e-06	4.07e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—MAPK1—melanoma	1.68e-06	4.04e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—EGFR—melanoma	1.68e-06	4.04e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—PIK3CA—melanoma	1.67e-06	4.03e-05	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—PIK3CD—melanoma	1.67e-06	4.03e-05	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—ALB—melanoma	1.65e-06	3.98e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—CYP1B1—melanoma	1.65e-06	3.97e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—MAPK3—melanoma	1.63e-06	3.92e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—TP53—melanoma	1.62e-06	3.9e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—MDM2—melanoma	1.59e-06	3.82e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—KRAS—melanoma	1.58e-06	3.82e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—MYC—melanoma	1.58e-06	3.82e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—ERBB2—melanoma	1.56e-06	3.77e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—MAPK1—melanoma	1.55e-06	3.73e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—EGFR—melanoma	1.55e-06	3.73e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—HRAS—melanoma	1.55e-06	3.73e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—PIK3CB—melanoma	1.54e-06	3.72e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—VCAN—melanoma	1.52e-06	3.65e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—CXCL8—melanoma	1.48e-06	3.58e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—IL6—melanoma	1.48e-06	3.57e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—KRAS—melanoma	1.46e-06	3.53e-05	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—PIK3CB—melanoma	1.46e-06	3.51e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—PIK3CA—melanoma	1.46e-06	3.51e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—CDKN1B—melanoma	1.45e-06	3.49e-05	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—PTGS2—melanoma	1.44e-06	3.48e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—CASP3—melanoma	1.42e-06	3.42e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—IL2—melanoma	1.42e-06	3.42e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—CCND1—melanoma	1.38e-06	3.33e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—PIK3CG—melanoma	1.37e-06	3.31e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—CTNNB1—melanoma	1.37e-06	3.3e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—AKT1—melanoma	1.37e-06	3.29e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—ABCB1—melanoma	1.36e-06	3.27e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—HRAS—melanoma	1.35e-06	3.25e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—PIK3CA—melanoma	1.34e-06	3.24e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—MMP9—melanoma	1.34e-06	3.23e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—CDKN1A—melanoma	1.34e-06	3.22e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—PTEN—melanoma	1.33e-06	3.22e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—NFKB1—melanoma	1.33e-06	3.2e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—PPARG—melanoma	1.33e-06	3.2e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—PRKCA—melanoma	1.32e-06	3.19e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—ERCC2—melanoma	1.31e-06	3.17e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—IL6—melanoma	1.29e-06	3.11e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—CYP17A1—melanoma	1.28e-06	3.08e-05	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—PTEN—melanoma	1.26e-06	3.03e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—PRKCA—melanoma	1.25e-06	3.01e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—HRAS—melanoma	1.24e-06	3e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—ERCC2—melanoma	1.24e-06	2.98e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—PIK3CD—melanoma	1.21e-06	2.91e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—GNA11—melanoma	1.21e-06	2.91e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—VEGFA—melanoma	1.2e-06	2.9e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—STAT3—melanoma	1.19e-06	2.88e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—ALB—melanoma	1.19e-06	2.88e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—NRAS—melanoma	1.19e-06	2.87e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—IL6—melanoma	1.19e-06	2.87e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—AKT1—melanoma	1.19e-06	2.87e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—FASN—melanoma	1.18e-06	2.85e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—SLC5A5—melanoma	1.16e-06	2.8e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—MAPK3—melanoma	1.14e-06	2.75e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—GNAQ—melanoma	1.12e-06	2.71e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—CD44—melanoma	1.12e-06	2.71e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—MYC—melanoma	1.11e-06	2.67e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—AKT1—melanoma	1.1e-06	2.65e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—MAPK1—melanoma	1.08e-06	2.61e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—EGFR—melanoma	1.08e-06	2.61e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—CYP1B1—melanoma	1.08e-06	2.59e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—PIK3CB—melanoma	1.05e-06	2.54e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—PTGS2—melanoma	1.04e-06	2.52e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—PIK3CG—melanoma	1.04e-06	2.5e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—KRAS—melanoma	1.02e-06	2.47e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—PPARG—melanoma	1e-06	2.41e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—PIK3CG—melanoma	9.77e-07	2.36e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—PPARG—melanoma	9.43e-07	2.27e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—PIK3CA—melanoma	9.41e-07	2.27e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—PIK3CD—melanoma	9.12e-07	2.2e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—TP53—melanoma	9.1e-07	2.19e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—PTEN—melanoma	9.1e-07	2.19e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—ALB—melanoma	9e-07	2.17e-05	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—PIK3CA—melanoma	8.88e-07	2.14e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—ABCB1—melanoma	8.86e-07	2.14e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—HRAS—melanoma	8.71e-07	2.1e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—PIK3CD—melanoma	8.59e-07	2.07e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—ALB—melanoma	8.48e-07	2.04e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—IL6—melanoma	8.33e-07	2.01e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—PRKCA—melanoma	8.16e-07	1.97e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—ERCC2—melanoma	8.09e-07	1.95e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—PIK3CB—melanoma	7.95e-07	1.92e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—PTGS2—melanoma	7.87e-07	1.9e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—AKT1—melanoma	7.69e-07	1.85e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—PIK3CB—melanoma	7.49e-07	1.81e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—PTGS2—melanoma	7.42e-07	1.79e-05	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—AKT1—melanoma	7.26e-07	1.75e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—PTEN—melanoma	6.87e-07	1.66e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—PTEN—melanoma	6.47e-07	1.56e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—PIK3CA—melanoma	6.42e-07	1.55e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—PIK3CG—melanoma	6.39e-07	1.54e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—PPARG—melanoma	6.17e-07	1.49e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—PIK3CD—melanoma	5.62e-07	1.35e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—ALB—melanoma	5.55e-07	1.34e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—AKT1—melanoma	5.24e-07	1.26e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—PIK3CB—melanoma	4.9e-07	1.18e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—PTGS2—melanoma	4.85e-07	1.17e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—PIK3CA—melanoma	4.84e-07	1.17e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—PIK3CA—melanoma	4.57e-07	1.1e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—PTEN—melanoma	4.23e-07	1.02e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—AKT1—melanoma	3.96e-07	9.54e-06	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—AKT1—melanoma	3.73e-07	8.99e-06	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—PIK3CA—melanoma	2.98e-07	7.19e-06	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—AKT1—melanoma	2.44e-07	5.88e-06	CbGpPWpGaD
